Mardia Samyoung Capillary Tubes Company Limited reported a standalone net profit of ₹105.06 lakh for the quarter ended June 30, 2026 (Q1FY27), marking an 8.4% decline from the ₹114.72 lakh profit recorded in the preceding quarter ended March 31, 2026. Revenue from operations fell sharply to ₹2,483.91 lakh from ₹6,111.74 lakh in Q4FY26. The results were approved by the Board of Directors at a meeting held on August 11, 2026, in Ahmedabad. The decline in profitability comes against a backdrop of significant governance concerns highlighted by statutory auditors regarding inventory verification and fund utilization.

The company’s statutory auditors, S.K. Bhavsar & Co., Chartered Accountants, issued a limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, containing multiple "Emphasis of Matter" paragraphs. The auditors stated they could not verify the physical stock or inventory as of June 30, 2026, as management failed to furnish a representation letter confirming its existence and condition. Consequently, the auditors could not comment on the valuation of inventory reflected in the financial statements.

Further material disclosures revealed significant gaps in transaction verification. The auditors noted that sales and purchase invoices necessary to verify transactions and the end-utilization of funds raised during the quarter were not made available for full verification. During the period, the company converted 1,17,15,000 warrants into equity shares, raising ₹15.82 crore (₹15,81,52,500) comprising face value and a share premium of ₹13.50 per share. Despite verifying the receipt of these funds, the auditors could not confirm their utilization for stated purposes due to missing documentation.

A critical concern involves interest-free advances aggregating ₹22.84 crore given by the company during the quarter. Supporting documentation for these advances was not provided, leaving the auditors unable to assess their recoverability or business rationale. Additionally, confirmations for certain trade receivable and payable balances were not obtained, and adequate alternative procedures could not be performed, limiting assurance on the accuracy of these balances.

Financial Performance Summary

The company also announced the shifting of its corporate office from Gandhinagar to Ahmedabad, effective August 11, 2026. The new address is Office No. A-404, Titanium Square, S.G. Highway, Thaltej, Ahmedabad. The Board meeting commenced at 08:00 PM and concluded at 09:00 PM on August 11, 2026.

What the Numbers Show

The divergence between the substantial capital infusion of ₹15.82 crore via warrant conversion and the simultaneous extension of ₹22.84 crore in interest-free advances raises questions about capital allocation efficiency. With revenue dropping over 59% quarter-on-quarter and auditors unable to verify inventory or trade balances, the financial statements present limited transparency into operational health. The absence of cost of materials consumed (reported as ₹0.00) alongside significant purchases of stock-in-trade (₹2,554.43 lakh) suggests potential classification nuances or reporting gaps that require further clarification from management.

Mardia Samyoung Capillary Tubes Company Limited has released its unaudited standalone financial results for the quarter ended September 30, 2025, showing a significant reduction in net loss compared to the same period last year.

Financial Highlights

The company's financial performance shows a marked improvement in its bottom line, with the net loss narrowing by 86.47% year-over-year. While the revenue figures for the previous year were not provided, the current quarter's revenue from operations stood at ₹976.20 lakhs.

Operational Performance

The cash flow from operating activities for the six months ended September 30, 2025, showed a significant improvement. The negative cash flow reduced from ₹253.46 lakhs in the previous year to ₹3.48 lakhs, indicating better operational efficiency and working capital management.

Corporate Governance

The board of directors approved these financial results at a meeting held on November 11, 2025. SK Bhavsar Co., the statutory auditors, issued a limited review report with an unmodified opinion on the financial results, providing assurance on the accuracy of the reported figures.

Outlook

While the company continues to report a net loss, the substantial reduction in the loss figure and improved cash flow position suggest that Mardia Samyoung Capillary Tubes may be on a path to recovery. However, investors should note that these are unaudited results and may be subject to changes upon final audit.

The company's ability to sustain this trend of reducing losses and potentially achieve profitability in the coming quarters will be crucial for its financial health and market perception. Stakeholders will likely keep a close eye on future announcements and audited results to gauge the company's long-term prospects.

Note: All financial figures are based on standalone results and may not represent the complete financial position of the company if it has subsidiaries or associates.